

REMARKS

The claims have been amended to more completely encompass the invention. The claims as amended are fully supported in the application as originally filed and contain no new matter.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version With Markings To Show Changes Made".

CONCLUSION

Applicant has submitted all fees believed to be necessary herewith. Should any additional fees or surcharges be deemed necessary, Examiner has authorization to charge fees or credit any overpayment to Deposit Account No. 23-3000.

The Examiner is invited to telephone the undersigned attorney if there are any questions.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.



Beverly A. Lyman, Ph.D., Reg. No. 41,961

2700 Carew Tower
441 Vine Street
Cincinnati, Ohio 45202
(513) 241-2324 - Voice
(513) 421-7269 - Facsimile
K:\HOFE\02\AMD Preliminary.wpd



VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS

Claim 3 has been canceled and claims 1, 4-7, 9, 20, 21, 30, 34, 35 and 39-41 have been amended as follows:

1. (AMENDED) A method for treating a patient having a condition affecting at least one layer of skin comprising administering in situ a physiologically acceptable formulation containing at least one [enzyme] hydrolase selective for a layer of skin affected by said condition in an amount and for a duration effective to remove said layer and treat said condition.

Cancel claim 3.

4. (AMENDED) The method of claim [3] 1 wherein said hydrolase is selected from the group consisting of esterases, glycosidases, proteases, phosphatases, thiolases, phospholipases, amidases, ceramidases, lipases, deaminases, nucleases and combinations thereof.

5. (AMENDED) The method of claim 1 wherein said [enzyme] hydrolase is selected from the group consisting of trypsin, chymotrypsin, papain, bromelain, dispase, thermolysin, ceramidase, lipase, glycosidase, deoxyribonuclease, ribonuclease and combinations thereof to treat an epidermal layer.

6. (AMENDED) The method of claim 1 wherein said [enzyme] hydrolase is selected from the group consisting of collagenase, elastase, and combinations thereof to treat a dermal layer.

7. (AMENDED) The method of claim 1 wherein said [enzyme] hydrolase is a lipase to treat a subcutaneous layer.

9. (AMENDED) The method of claim 1 wherein the [enzyme] hydrolase is selected from the group consisting of trypsin, chymotrypsin, papain, collagenase, pepsin A, elastase, exopeptidases, aminopeptidases, endopeptidases, bromelain, chymotrypsin C, metridin, trypsin, thrombin, plasmin, enteropeptidase, alpha-lytic endopeptidase, prolyl oligopeptidase, brachyurin, plasma kallikrein, tissue kallikrein, pancreatic elastase, leukocyte elastase, chymase, cerevisin, hypodermin C, endopeptidase La, alpha-renin, leucyl endopeptidase, tryptase, kexin, subtilisin, oryzin, endopeptidase K, thermomycolin, thermitase, endopeptidase So, tissue plasminogen activator, pancreatic endopeptidase E, pancreatic elastase II, urine plasminogen activator, cathepsin B, facain, chymopapain, asclepain, clostripain, streptopain, actinidain, cathepsin L, cathepsin H, calpain, cathepsin T, glycyl endopeptidase, cathepsin S, caricain, ananain, stem bromelain, fruit bromelain, legumain, histolysain, pepsin B, gastricsin, chymosin, cathepsin D, retropepsin, aspergillopepsin I, aspergillopepsin II, penicillopepsin, rhizopuspepsin, endothiapepsin, mucorpepsin, candidapepsin, saccharopepsin, rhodotorulapepsin, physaropepsin, acrocylindropepsin, polyporopepsin, pycnoporopepsin, scytalidopepsin A, scytalidopepsin

B, xanthomonaepsin, pseudomonaepsin, cathepsin E, atrolisin, microbial collagenase, leucolysin, interstitial collagenase, neprilysin, matrix metalloproteinases dispase, thermolysin, V8 protease, ribonuclease, deoxyribonuclease[,] and combinations thereof.

20. (AMENDED) A topically applied composition for treating a patient having a skin condition affecting at least one epidermal, and/or dermal layer, and/or subcutaneous layer comprising a hydrolase in a pharmaceutically acceptable formulation, said [enzyme] hydrolase in an amount in the range of about $1 \times 10^{-5}\%$ by weight to about 10% by weight of said formulation.

21. (AMENDED) The composition of claim 20 wherein said [enzyme] hydrolase is [a hydrolase] selected from the group consisting of esterases, glycosidases, proteases, phosphatases, thiolases, phospholipases, amidases, ceramidases, lipases, deaminases, nucleases and combinations thereof.

30. (AMENDED) A method to target skin treatment of an affected area comprising providing to said affected area a composition containing at least one [enzyme] hydrolase in an amount and formulation effective to selectively target skin removal in said affected area.

34. (AMENDED) A method for treating a condition affecting skin comprising applying a composition to the affected skin, the composition containing at least one [enzyme] hydrolase at a concentration selective for regulating depth of skin treatment and applied to an area selective for regulating a radial surface of skin treatment.

35. (AMENDED) The method of claim 34 wherein the [enzyme] hydrolase is a protease.

39. (AMENDED) The method of claim 34 wherein the [enzyme] hydrolase is a protease to treat an epidermal layer.

40. (AMENDED) The method of claim 34 wherein a relatively short duration of exposure and a relatively low [enzyme] hydrolase concentration is used to treat a condition affecting an epidermal layer.

41. (AMENDED) The method of claim 34 wherein a relatively long duration of exposure and a relatively high [enzyme] hydrolase concentration is used to treat a condition affecting a dermal layer.